User:Brian Boyle/Sandbox 1: Difference between revisions
Brian Boyle (talk | contribs) No edit summary |
Brian Boyle (talk | contribs) No edit summary |
||
| Line 13: | Line 13: | ||
[[Image:Kac N83 PyMOL Image.JPG | thumb | 400x400px | BRPF1 Asn-83 forms a hydrogen bond with the carbonyl moiety of the acetyllysine residue. The bromodomain is shown in green. The H4K12ac peptide is shown in cyan. (PDB entry 4QYD)]] | [[Image:Kac N83 PyMOL Image.JPG | thumb | 400x400px | BRPF1 Asn-83 forms a hydrogen bond with the carbonyl moiety of the acetyllysine residue. The bromodomain is shown in green. The H4K12ac peptide is shown in cyan. (PDB entry 4QYD)]] | ||
The BRPF1 bromodomain has been shown to recognize and bind to various acetylated lysine marks on the N-terminal tails of histones tails <ref name="Glass1" />. | The BRPF1 bromodomain has been shown to recognize and bind to various acetylated lysine marks on the N-terminal tails of histones tails <ref name="Glass1" />. It preferentially binds to histone H4 acetylated at positions K5 ([[2rs9]]), K8, and K12 ([[4qyd]]) as well as H3 and H2A (([[4qyl]]) at position K14 and K5, respectively<ref name="Obi" />,<ref name="Glass1" />. Interestingly, the BRPF1 bromodomain has also been shown to bind di-acetylated histone peptides with high affinity, including H4K5acK8ac and H4K5acK12ac <ref name="Obi" />. Acetyllysine recognition is coordinated by a number of residues in the bromodomain's binding pocket. Using NMR chemical shift perturbation experiments, Glass et al. reported several <scene name='91/910741/Nmr_resi_h4_binding/1'>key residues</scene> the undergo conformational changes upon histone H4 ligand binding (I27, L34, E36, V37, N83, and I88)<ref name="Obi" />. Notably, asparagine 83 was among these. The interaction between the amide nitrogen of asparagine with the carbonyl of the acetyllysine group is conserved in all bromodomains and is necessary for binding to occur <ref name ="Obi" />,<ref name ="Lubula_2014" />. Furthermore, the tyrosine 40 and isoleucine 127 stabilize the acetyllysine residue through water-mediated hydrogen bonds<ref name="Lubula_2014" />. | ||
== '''PWWP Domain''' == | == '''PWWP Domain''' == | ||
Revision as of 19:45, 3 May 2022
| ||||||||||||
BRPF1 Association with the MOZ HAT Complex
The MOZ Histone Acetyltransferase Complex is a tetramer consisting of MEAF6, ING5, BRPF1 and MOZ or MORF[1]. Within BRPF1, there are two non-chromatin-binding modules surrounding the PZP domain that are responsible for its association with the MOZ HAT Complex. On the N-terminal side of the PZP, lies the MOZ/MORF binding domain[2]. On the other side of the PZP domain, there is a small module involved in binding to ING5 and MEAF6[3]. BRPF1 seems to be required for the formation of the MOZ HAT complex, as it acts as a bridge associating MOZ or MORF with ING5 and MEAF6[3].
Evolutionary Relationships
Bromodomains are categorized into several families based on sequence and structural similarity. The BRPF1 bromodomain belongs to family IV of bromodomains[4].
Links to Human Disease
BRPF1 has been implicated in the progression of several cancers. Chromosomal translocations of the gene encoding MOZ (a subunit in the MOZ HAT complex) have been linked to the development of acute myeloid leukemia [5]. The crucial role of BRPF1 in this complex has made it the subject of many studies in order to understand how this mutation leads to a cancer phenotype. Another study reported an association between upregulation of the BRPF1 gene and poor survival rates in hepatocellular carcinoma patients [6].
Mutations within the gene itself have been associated with neurological disorders and widespread reduced histone acetylation [7].
Available Structures
References
- ↑ Cite error: Invalid
<ref>tag; no text was provided for refs namedKlein - ↑ Lalonde ME, Avvakumov N, Glass KC, Joncas FH, Saksouk N, Holliday M, Paquet E, Yan K, Tong Q, Klein BJ, Tan S, Yang XJ, Kutateladze TG, Cote J. Exchange of associated factors directs a switch in HBO1 acetyltransferase histone tail specificity. Genes Dev. 2013 Sep 15;27(18):2009-24. doi: 10.1101/gad.223396.113. PMID:24065767 doi:https://dx.doi.org/10.1101/gad.223396.113
- ↑ 3.0 3.1 Ullah M, Pelletier N, Xiao L, Zhao SP, Wang K, Degerny C, Tahmasebi S, Cayrou C, Doyon Y, Goh SL, Champagne N, Cote J, Yang XJ. Molecular architecture of quartet MOZ/MORF histone acetyltransferase complexes. Mol Cell Biol. 2008 Nov;28(22):6828-43. doi: 10.1128/MCB.01297-08. Epub 2008 Sep , 15. PMID:18794358 doi:10.1128/MCB.01297-08
- ↑ Lloyd JT, Glass KC. Biological function and histone recognition of family IV bromodomain-containing proteins. J Cell Physiol. 2018 Mar;233(3):1877-1886. doi: 10.1002/jcp.26010. Epub 2017 Jun , 13. PMID:28500727 doi:https://dx.doi.org/10.1002/jcp.26010
- ↑ Cite error: Invalid
<ref>tag; no text was provided for refs namedObi - ↑ Cheng CL, Tsang FH, Wei L, Chen M, Chin DW, Shen J, Law CT, Lee D, Wong CC, Ng IO, Wong CM. Bromodomain-containing protein BRPF1 is a therapeutic target for liver cancer. Commun Biol. 2021 Jul 20;4(1):888. doi: 10.1038/s42003-021-02405-6. PMID:34285329 doi:https://dx.doi.org/10.1038/s42003-021-02405-6
- ↑ Cite error: Invalid
<ref>tag; no text was provided for refs namedYan